NEW YORK (GenomeWeb News) — Epigenomics yesterday said it has transferred its PCR-based prostate cancer prognostic test to Affymetrix’ GeneChip platform.
The company said a concordance study showed a 98-percent agreement between the two platforms.
Epigenomics said the development of its test is “on track” and expecting to begin clinical trials in the US and Europe some time in 2007.
Epigenomics added that the demonstrating concordance should make regulatory clearance easier. The company also will file an Investigational Device Exemption in the first quarter of 2007.
The prostate test uses DNA methylation patterns to identify which patients who had undergone prostatectomies are at risk of recurrence, which happens in about one in seven cases.
The complete version of this article appears in this week's issue of BioArray News, a GenomeWeb News sister publication.